Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist |
| |
Authors: | Yuyama Hironori Sanagi Masanao Koakutsu Akiko Mori Mikiko Fujimori Akira Harada Hironori Sudoh Katsumi Miyata Keiji |
| |
Institution: | Pharmacology Laboratories Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co, Ltd, 21, Miyukigaoka, Ibaraki Tsukuba 305-8585, Japan. yuyama@yamamouchi.co.jp |
| |
Abstract: | We describe here the pharmacology of (E)-N-6-methoxy-5-(2-methoxyphenoxy)2,2'-bipyrimidin]-4-yl]-2-phenylethenesulfonamide monopotassium salt (YM598), a novel selective endothelin ET(A) receptor antagonist synthesized through the modification of the ET(A)/ET(B) non-selective antagonist, bosentan. YM598 inhibited 125I]endothelin-1 binding to cloned human endothelin ET(A) and ET(B) receptor, with K(i) of 0.697 and 569 nM, and inhibited endothelin-1-induced increases in intracellular Ca(2+) concentration in human and rat endothelin ET(A) receptor. YM598 also inhibited endothelin-1-induced vasoconstriction in isolated rat aorta with a pA(2) value of 7.6. In vivo, YM598 inhibited the pressor response to big endothelin-1, a precursor peptide of endothelin-1. DR(2) values of YM598 in pithed rats were 0.53 mg/kg, i.v. and 0.77 mg/kg, p.o., and its antagonism in conscious rats was maintained for more than 6.5 h at 1 mg/kg, p.o. In contrast, YM598 had no effect on the sarafotoxin S6c-induced depressor or pressor responses. YM598 showed not only superior antagonistic activity and higher-selectivity for endothelin ET(A) receptor in vitro, but at least a 30-fold higher potency in vivo than bosentan. In conclusion, YM598 is a potent and orally active selective endothelin ET(A) receptor antagonist. |
| |
Keywords: | YM598 Antagonist Endothelin ETA receptor |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|